OUTLOOK THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Cash and Cash Equivalents, Period Increase (Decrease) of $12.31 million for the 9-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-14
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $13.87M, a 136.69% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$72.25K.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$1.49M, a 113.98% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$10.08M, a 430.94% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$1.47M, a 276.11% decline from fiscal 2017.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $833.63K.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$6.72M, a 199.96% decline from fiscal 2015.
- OUTLOOK THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $6.72M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | $13.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | $13.80M derived: sum of 2 quarters · filed 2019-08-14 | $12.31M 10-Q · filed 2019-08-14 | $2.23M derived: sum of 4 quarters · filed 2019-08-14 |
| 2019-03-31 | -$72.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15 | -$1.56M 10-Q · filed 2019-05-15 | -$11.64M derived: sum of 3 quarters · filed 2019-05-15 | -$5.78M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-12-31 | -$1.49M 10-Q · filed 2019-02-14 | -$11.57M derived: sum of 2 quarters · filed 2019-02-14 | -$5.71M derived: sum of 3 quarters · filed 2019-08-14 | -$13.61M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-09-30 | -$10.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | -$4.22M derived: sum of 2 quarters · filed 2019-08-14 | -$12.12M derived: sum of 3 quarters · filed 2019-08-14 | -$1.47M 10-K · filed 2018-12-18 |
| 2018-06-30 | $5.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | -$2.04M derived: sum of 2 quarters · filed 2019-08-14 | $8.61M 10-Q · filed 2019-08-14 | $11.66M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15 | $2.75M 10-Q · filed 2019-05-15 | $5.80M derived: sum of 3 quarters · filed 2019-05-15 | $5.86M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $10.65M 10-Q · filed 2019-02-14 | $13.70M derived: sum of 2 quarters · filed 2019-02-14 | $13.76M derived: sum of 3 quarters · filed 2019-02-14 | $11.76M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-09-30 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | $3.10M derived: sum of 2 quarters · filed 2018-12-18 | $1.11M derived: sum of 3 quarters · filed 2018-12-18 | $833.63K 10-K · filed 2018-12-18 |
| 2017-06-30 | $58.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | -$1.94M derived: sum of 2 quarters · filed 2018-08-14 | -$2.21M 10-Q · filed 2018-08-14 | -$13.42M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | -$2.27M 10-Q · filed 2018-05-15 | -$13.47M derived: sum of 3 quarters · filed 2018-05-15 | -$2.76M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | -$273.35K 10-Q · filed 2018-02-14 | -$11.48M derived: sum of 2 quarters · filed 2018-02-14 | -$763.66K derived: sum of 3 quarters · filed 2018-02-14 | -$3.50M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-09-30 | -$11.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | -$490.31K derived: sum of 2 quarters · filed 2017-12-29 | -$3.23M derived: sum of 3 quarters · filed 2017-12-29 | -$6.72M 10-K · filed 2017-12-29 |
| 2016-06-30 | $10.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-14 | $7.97M derived: sum of 2 quarters · filed 2017-08-14 | $4.48M 10-Q · filed 2017-08-14 | $8.17M derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | -$2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-15 | -$6.23M 10-Q · filed 2017-05-15 | -$2.54M derived: sum of 3 quarters · filed 2017-05-15 | $2.42M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$3.49M 10-Q · filed 2017-02-14 | $201.69K derived: sum of 2 quarters · filed 2017-02-14 | $5.16M derived: sum of 3 quarters · filed 2017-02-14 | |
| 2015-09-30 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-29 | $8.65M derived: sum of 2 quarters · filed 2016-12-29 | $6.72M 10-K · filed 2016-12-29 | |
| 2015-06-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-15 | $3.03M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$1.92M 10-Q · filed 2016-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |